Ketamine Treatment

HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), announced plans to acquire a network of interventional psychiatry clinics, focusing on ketamine treatments. The acquisition and financing agreements, valued at $30 million, are backed by a qualified lender. The...

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  Research Disorders due to substance use: Hallucinogens and MDMA-related...

Defense Dept. Funds Ketamine Study For PTSD Treatment  A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos...

Supermodel Chrissy Teigen recently celebrated her 38th birthday surrounded by her loved ones and ketamine therapy. Via her Instagram account, she said the psychedelic session made her see “space and time” as well as baby Jack “and some weird penguins,”...

A Department of Defense (DOD) Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics (...

Healthcare company Johnson & Johnson (J&J) (NYSE: JNJ) shared its financial outcomes for the third quarter of 2023, reflecting:  Total reported sales of $21,351 million, a 6.8% increase compared to the same period in 2022. Of which U.S. sales totaled $11,996 million (...

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. (OTCMKTS: DMTTF) held their respective annual general and special shareholders meetings on October 12. They announced that...

The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product.  What Happened: The so-called goal date for PharmaTher's KETARX drug is April 29, 2024, according to the FDA. From...

Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, to the FDA.  The company expects the agency will perform an expedited review of its ANDA, and ...

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug SPC-15.  The company aims to combine the liquid nasal formulation and SPC-15’s novel...

As part of its business restructuring process and following its London clinics business sale, UK-based biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) has sold its Norwegian clinics businesses in a management buyout transaction. Awakn will receive a fee for the acquisition of both clinics, ...

Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic ketamine KETARX to the FDA. The filing of the pre-submission correspondence is expected to help...

Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalgia and chronic pain as the initially targeted indications.  The new project includes...

Clinical-stage biopharma company Seelos Therapeutics Inc. (NASDAQ: SEEL) reported financial results and clinical updates corresponding to the first quarter ended March 31, 2023. Quarterly numbers show: Total cash and cash equivalents of $14.1 million as of March 31, 2023, compared to the $15.5...

Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and development. The patent granted by the USPTO covers the use of biomarkers in...